RPRXN Stock Chart & Stats
$1049.21
$0.00(0.00%)
At close: 4:00 PM EDT
$1049.21
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$624.01 - $1,049.21
Previous CloseN/A
Volume0.00
Average Volume (3M)618.00
Market Cap
$588.63B
Enterprise Value$42.30K
Total Cash (Recent Filing)$836.99M
Total Debt (Recent Filing)$8.96B
Price to Earnings (P/E)25.1
Beta0.20
Next Earnings
Nov 11, 2026EPS Estimate
20.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.41
Shares Outstanding445,277,340
10 Day Avg. Volume1,355
30 Day Avg. Volume618
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.58
Price to Sales (P/S)7.02
P/FCF Ratio6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,111.37Price Target Upside5.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)90.3
Revenue Forecast (FY)$59.26B
Bulls Say, Bears Say
Bulls Say
Recurring Royalty Growth And Raised GuidanceGrowing recurring royalty receipts provide durable visibility because they are tied to commercial drug sales and contractual economics. The raised 2026 guidance also indicates management sees continued portfolio strength, supporting cash generation and investment capacity over coming quarters.
Strong Profitability And Cash ConversionExceptionally high margins and strong cash conversion are structural benefits of the royalty model, which avoids many operating costs associated with drug development and commercialization. Robust cash generation supports debt service, shareholder returns, and continued royalty acquisitions.
Expanding Development Pipeline And Deal ExecutionA larger development-stage pipeline and active acquisition program can broaden future royalty sources beyond the existing portfolio. The cited historical success rate and substantial capital deployment suggest Royalty Pharma is building long-term growth options while recycling capital into additional assets.
Bears Say
Meaningful And Rising LeverageThe rising debt burden reduces financial flexibility if portfolio receipts weaken or acquisition opportunities become less attractive. Although profitability and cash flow currently provide support, higher leverage increases the importance of disciplined capital allocation and sustained royalty collections.
Product-specific Revenue HeadwindsLoss of exclusivity, biosimilar competition, and potential policy effects can pressure sales of underlying products and therefore reduce royalty receipts. These are identifiable portfolio headwinds that may weigh on growth and require offsetting contributions from other assets.
Exposure To Development-stage Trial OutcomesDevelopment-stage investments offer substantial upside but do not yet provide dependable commercial cash flows. If pivotal trials fail or are delayed, expected royalties and returns may not materialize, making part of the pipeline’s future growth dependent on clinical execution.
Royalty Pharma News
RPRXN FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $624.01 and its highest was $1049.21 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $588.63B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Nov 11, 2026 which is in 62 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Aug 05, 2026. The company reported $22.425 earnings per share for the quarter, beating the consensus estimate of $21.61 by $0.815.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC does not currently pay dividends.
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 20.05.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 445,277,340 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $22.425 in its last earnings report, beating expectations of $21.61. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in MX:RPRXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,111.37 (5.92% Upside)
$1,111.37 (5.92% Upside)
Blogger Sentiment
Neutral
MX:RPRXN Sentiment 60%
Sector Average 60%
Sector Average 60%
News Sentiment
Bullish
Bullish news 71%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.22%
12-Months-Change
Fundamentals
Return on Equity
1.54%
Trailing 12-Months
Asset Growth
8.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Royalty Pharma PLC
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRXN Company Deck
RPRXN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple strong positives: double‑digit recurring cash flow growth, raised full‑year guidance, disciplined capital deployment (including a strategic cliramitug purchase), expanded development‑stage pipeline with high historical success rates, robust cash generation, and an investment‑grade credit upgrade. Lowlights were present but largely manageable: a material decline in milestone/contract receipts (one‑time prior period effect), specific product headwinds (Promacta, biosimilar Tysabri, IRA), dependence on future pivotal trial outcomes for some investments, modestly higher expected operating expense rates in H2, and geopolitical/regulatory uncertainty in China. Overall, the positives—strong growth, improved guidance, financial flexibility, and portfolio expansion—substantially outweigh the risks and near‑term headwinds.View all MX:RPRXN earnings summariesRPRXN Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRXN Stock 12 Month Forecast
Average Price Target
$1,111.37
▲(5.92% Upside)
Technical Analysis
Corcept Therapeutics
―
Prestige Consumer Healthcare
―
Sinovac Biotech
―
Kiniksa Pharmaceuticals
―
Liquidia Technologies
―